Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
O43556
UPID:
SGCE_HUMAN
Alternative names:
-
Alternative UPACC:
O43556; B2R8N2; D6W5Q8; E9PF60; G5E9K6; Q6L8P0; Q75MH8; Q8NFG8; Q8WW28
Background:
Epsilon-sarcoglycan, encoded by the gene with accession number O43556, is a crucial component of the sarcoglycan complex. This complex is part of the larger dystrophin-glycoprotein complex, linking the F-actin cytoskeleton to the extracellular matrix. This linkage is vital for the integrity of muscle tissue.
Therapeutic significance:
Dystonia 11, myoclonic, a form of dystonia characterized by involuntary muscle contractions and alleviated by alcohol, is associated with variants in the epsilon-sarcoglycan gene. Understanding the role of epsilon-sarcoglycan could lead to novel therapeutic strategies for this condition.